Ligand binding assays in the 21st century laboratory: Recommendations for characterization and supply of critical reagents

AAPS Journal

Volumn 14, Issue 2, 2012, Pages 316-328

  O'Hara, Denise M ^a   Theobald, Valerie ^b   Egan, Adrienne Clements ^c   Usansky, Joel ^d   Krishna, Murli ^e   TerWee, Julie ^f   Maia, Mauricio ^g   Spriggs, Frank P ^a   Kenney, John ^h   Safavi, Afshin ⁱ   Keefe, Jeannine ^j  

^a PFIZER INC   (United States)

^b SANOFI   (France)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Thermo Fisher Scientific   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f AMGEN INC   (United States)

^g GENENTECH INC   (United States)

^h Antibody Solutions   (United States)

ⁱ Hamner Institutes for Health Sciences   (United States)

^j BIOGEN   (United States)

more..

Author keywords

Characterization; Critical reagents; Data management; Inventory; Knowledge database; Ligand binding assays

Indexed keywords

BIOLOGICAL MARKER; CHEMICAL COMPOUND; DRUG ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE DERIVATIVE; POLYCLONAL ANTIBODY; PROTEIN DERIVATIVE; REAGENT; RECOMBINANT PROTEIN;

ARTICLE; BINDING ASSAY; BIOENGINEERING; CELL LINE; CHEMICAL ANALYSIS; CHEMOSENSITIVITY; CONSENSUS; DRUG DEVELOPMENT; DRUG RESEARCH; IMMUNE RESPONSE; IMMUNOGENICITY; KNOWLEDGE BASE; LABORATORY TEST; LIGAND BINDING; METHODOLOGY; MOLECULAR GENETICS; PHYSICAL CHEMISTRY; POSTMARKETING SURVEILLANCE; QUALITY CONTROL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STORAGE TEMPERATURE; WESTERN BLOTTING;

ANIMALS; DRUG DISCOVERY; HUMANS; INDICATORS AND REAGENTS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 84860720468     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9334-9     Document Type: Article

References (61)

1. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 2007;9(2):E117-E122. (Pubitemid 46690951)
2. Cawkill D, Eaglestone SS. Evolution of cell-based reagent provision. Drug Discov Today. 2007;12(19-20):820-5. (Pubitemid 47539971)
3. Mairal T, Cengiz Özalp V, Lozano Sánchez P, Mir M, Katakis I, O'Sullivan CK. Aptamers: molecular tools for analytical applications. Anal Bioanal Chem. 2008;390(4):989-1007. (Pubitemid 351207799)
4. Tremblay GA, Oldfield PR. Bioanalysis of siRNA and oligonu-cleotide therapeutics in biological fluids and tissues. Bioanalysis. 2009;1(3):595-609.
5. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312-28. (Pubitemid 43237862)
6. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res. 2005;22(4):499-511. (Pubitemid 40603246)
7. Desilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20(11):1885-900. (Pubitemid 37449466)
8. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007;321(1-2):1-18. (Pubitemid 46454303)
9. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1-2):1-16. (Pubitemid 38900899)
10. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267-81.
11. O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V. Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods. 2011;363(2):120-34.
12. Good Laboratory Practice for Nonclinical Laboratory Studies, Title 21 CFR Part 58.83 (2007).
13. Rup B, O'Hara D. Critical ligand binding reagent preparation/selection: when specificity depends on reagents. AAPS J. 2007;9 (2):E148-E155. (Pubitemid 46812920)
14. Staack RF, Stracke JO, Stubenrauch K, Vogel R, Schleypen J, Papadimitriou A. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. Bioanalysis. 2011;3(5):523-34.
15. Bjerner J, Børmer OP, Nustad K. The war on heterophilic antibody interference. Clin Chem. 2005;51(1):9-11. (Pubitemid 40024005)
16. Ismail AAA. Interference from endogenous antibodies in automated immunoassays: what laboratorians need to know. J Clin Pathol. 2009;62(8):673-8.
17. Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clinica Chimica Acta. 2002;325(1-2):1-15. (Pubitemid 35279621)
18. Altinier S, Varagnolo M, Zaninotto M, Boccagni P, Plebani M. Heterophilic antibody interference in a non-endogenous molecule assay: an apparent elevation in the tacrolimus concentration. Clinica Chimica Acta. 2009;402(1-2):193-5.
19. Kahn MN, Findlay JWA, editors. Ligand binding assays: development, validation and implementation in the drug development arena. Hoboken: John Wiley & Sons; 2010.
20. DeForge LE, Loyet KM, Delarosa D, Chinn J, Zamanian F, Chuntharapai A, et al. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J Immunol Methods. 2010;362(1-2):70-81.
21. Preissner CM, Dodge LA, O'Kane DJ, Singh RJ, Grebe SKG. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem. 2005;51(1):208-10. (Pubitemid 40024033)
22. Spencer DV, Nolte FS, Zhu Y. Heterophilic antibody interference causing false-positive rapid human immunodeficiency virus antibody testing. Clinica Chimica Acta. 2009;399(1-2):121-2.
23. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods. 2000;235(1-2):71-80. (Pubitemid 30089785)
24. Levinson SS. Antibody multispecificity in immunoassay interference. Clin Biochem. 1992;25(2):77-87.
25. Tatarewicz S, Miller JM, Swanson SJ, Moxness MS. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods. 2010;357(1-2):10-6.
26. Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011;13(1):99-110.
27. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods. 2005;304(1-2):189-95. (Pubitemid 41262233)
28. Wild DG, editor. The immunoassay handbook. 3rd ed. Kidlington: Elsevier Science; 2005.
29. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256 (5517):495-7.
30. Milstein C. With the benefit of hindsight. Immunol Today. 2000;21(8):359-64. (Pubitemid 30612295)
31. Subramanian G, editor. Antibodies: volume 2: novel technologies and therapeutic use. New York, NY: Kluwer Academic/Plenum Publishers; 2004.
32. Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci USA. 1995;92 (20):9348-52.
33. Bradbury ARM, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004;290(1-2):29-49. (Pubitemid 38917129)
34. Lipovsek D, Plückthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods. 2004;290(1-2):51-67. (Pubitemid 38917130)
35. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433-55.
36. Cohen AD, Boyer JD, Weiner DB. Modulating the immune response to genetic immunization. FASEB J. 1998;12(15):1611-26. (Pubitemid 28553656)
37. Sundaram P, Xiao W, Brandsma JL Particle-mediated delivery of recombinant expression vectors to rabbit skin induces high-titered polyclonal antisera (and circumvents purification of a protein immunogen). Nucleic Acids Res. 1996;24(7):1375-7. (Pubitemid 26102691)
38. Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356 (6365):152-4.
39. Witkowski PT, Bourquain DR, Hohn O, Schade R, Nitsche A. Gene gun-supported DNA immunisation of chicken for straightforward production of poxvirus-specific IgY antibodies. J Immunol Methods. 2009;341(1-2):146-53.
40. Englebienne P. Immune and receptor assays in theory and practice. Boca Raton: CRC Press; 2000.
41. Gaberc-Porekar V, Zore I, Podobnik B, Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Dev. 2008;11(2):242-50. (Pubitemid 351281064)
42. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug Chem. 2010;21(7):1264-70.
43. Babu S. Criteria for CMO selection. Am Pharm Outsourcing. 2009;10(5):10-5.
44. Dellva P. Managing outsourcing relationships: what to do? What not to do? Am Pharm Outsourcing. 2003;4(4):30-3. (Pubitemid 37098681)
45. Bock I, Dhayalan A, Kudithipudi S, Brandt O, Rathert P, Jeltsch A. Detailed specificity analysis of antibodies binding to modified histone tails with peptide arrays. Epigenetics. 2011;6(2):256-63.
46. Hawe A, Sutter M, Jiskoot W Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res. 2008;25(7):1487-99.
47. Hawe A, Friess W, Sutter M, Jiskoot W Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal Biochem. 2008;378(2):115-22.
48. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamida-tion, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10 (4):307-77. (Pubitemid 24021947)
49. Tsai PK, Bruner MW, Irwin JI, Ip CCY, Oliver CN, Nelson RW, et al. Origin of the isoelectric heterogeneity of monoclonal immunoglobulin h1B4. Pharm Res. 1993;10(11):1580-6. (Pubitemid 23325659)
50. Liu H, Caza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci. 2008;97(7):2426-47.
51. Manningc M, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6(11):903-18. (Pubitemid 20078439)
52. Kueltzo LA, Wang W, Randolph TW, Carpenter JF. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci. 2008;97(5):1801-12.
53. Jiskoot W, Beuvery EC, De Koning AAM, Herron JN, Crommelin DJA. Analytical approaches to the study of monoclonal antibody stability. Pharm Res. 1990;7(12):1234-41.
54. Ritter N, Wiebe M. Validating critical reagents used in CGMP analytical testing: Eensuring method integrity and reliable assay performance. BioPharm. 2001;14(5):12-21. (Pubitemid 32458295)
55. ICH. Q2b. Guidance for industry: validation of analytical procedures methodology 2001.
56. Simonet BM. Quality control in qualitative analysis. TrAC-Trends Anal Chem. 2005;24(6):525-31. (Pubitemid 40798120)
57. Bowsher RR, Sailstad JM. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand. J Pharm Biomed Anal. 2008;48(5):1282-9.
58. Nowatzke W. Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development. Bioanalysis. 2010;2(2):237-47.
59. Crowther JR. The ELISA guidebook. 2nd ed. New York: Humana Press; 2010.
60. Ezzelle J, Rodriguez-Chavez IR, Darden JM, Stirewalt M, Kunwar N, Hitchcock R, et al. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal. 2008;46(1):18-29. (Pubitemid 350216340)
61. Ruttenberg A, Clark T, Bug W, Samwald M, Bodenreider O, Chen H, et al. Advancing translational research with the Semantic Web. BMC Bioinformatics. 2007;8(SUPPL. 3).